FinalDose
FinalDose is a YC Spring 2026 (P26) company. Based in London, England, United Kingdom. Team of 5.
About FinalDose
Summary
FinalDose builds a programmable DNA-targeting drug designed to seek out and destroy cells based on genetic recognition of disease-causing sequences. A single molecular platform accepts any diseased genetic code as its targeting input, replacing the need for a separate drug candidate for each target. The company is starting with cancer, with the stated goal of reaching the large share of genetic targets that conventional small-molecule and biologic drugs cannot address.
From the Y Combinator listing
Programmable DNA drug destroying all cancers, unlocking 80% of targets
FinalDose is building the first programmable drug - a single smart drug molecule that you can insert any diseased genetic code and it can search and destroy cells upon DNA recognition. Unlocking 80% of undruggable targets today. Starting with all cancers.
Facts
- Healthcare / Healthcare -> Therapeutics
- London, England, United Kingdom
- 5
- Active
- Early
Founders (3)
- Jeff Liu
- Li-Yao Huang
- Steven Lin
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works